Novanta Inc. (NOVT)
OvervaluedFundamental
55
Price
$140.80
Market Cap
$5.29B
Part 1 · What the company is worth
Overview
Novanta Inc., together with its subsidiaries, provides precision medicine, precision manufacturing, medical solutions, robotics and automation solutions, and advanced surgery solutions in the United States and internationally. The company operates Automation Enabling Technologies and Medical Solutions segments. The Precision Medicine and Manufacturing segment designs, manufactures, and markets laser beam steering and scanning solutions, laser sources, robotic and precision motion, robotic end-of-arm tooling, and bearing spindles. This segment serves advanced industrial processes, advanced industrial and medical robotics, other medical and life science automation applications, and medical laser procedures, such as ophthalmology applications. The Medical Solutions segment provides a range of medical grade technologies, including medical insufflators, pumps, and related disposables; imaging, identification and RFID solutions; advanced motion control solutions; and light engines, and integrated operating room technologies. The company was formerly known as GSI Group, Inc. and changed its name to Novanta Inc. in May 2016. Novanta Inc. was incorporated in 1968 and is based in Bedford, Massachusetts.
No editorial profile for this company yet
Direct competitors
Who this company fights with for the same customers
Generated with artificial intelligence on September 19, 2026, shared with all users
Named by Novanta as a major Photonics competitor: it supplies the same OEM customers with laser sources, optics and beam-delivery subsystems for industrial processing and medical devices.
Named by Novanta as a major Photonics competitor: both sell galvanometer-based laser beam-steering scan heads to the same industrial and medical laser-system builders.
Novanta names Omron Microscan Systems as a major Vision competitor: the two compete for the same factory-automation and medical-device OEMs buying machine vision and barcode reading subsystems.
Named by Novanta as a major Precision Motion competitor: both sell optical encoders and precision position-feedback devices to machine-tool, semiconductor and medical equipment makers.
Named by Novanta as a major Vision competitor: Barco's healthcare visualization business competes directly with Novanta's surgical and diagnostic display systems sold to medical OEMs and hospitals.
Named by Novanta as a major Precision Motion competitor: both supply precision positioning stages and motion subsystems to the same photonics, semiconductor and life-science instrument builders.
Balance Sheet & Liquidity
Revenue
$1.03B
Trailing 12 months (through 7/3/2026)
Net Income
$62M
Trailing 12 months (through 7/3/2026)
Free Cash Flow
$48M
Total Equity
$1.31B
Total Liabilities
$493M
Current Ratio
4.57
Interest Coverage
-
Debt/EBITDA
1.83
Earnings Per Share
Revenue & Net Income
Free Cash Flow
Income Breakdown
Historical statement
Margins over time
Debt over time
How heavy the debt is
Growth grid
Growth — Revenue
Fair Value Estimation
Fair Value
$89.96
Current Price
$140.80
Margin of Safety
-56.5%
Fair Value Range
$58.47 - $121.44
Spread across the valuation methods used, not a statistically calibrated confidence interval.
Estimation Methods
Valuation Metrics
P/E Ratio
89.68
ROE
4.1%
P/B Ratio
3.29
P/FCF
46.59
Gross Margin
44.5%
ROIC
3.9%
Profitability Radar
Value Creation (Economic Moat)
ROIC
3.9%
WACC
13.3%
ROIC − WACC
-9.4 pp
ROIC is below the cost of capital — the company is destroying value for every dollar invested.
Fundamental Analysis Criteria
Passed (15)
- EPS shows upward trend
- Price CAGR 21.27%
- Gross margin 44.5%
- Debt/equity ratio
- Operating margin 9.0%
- Positive free cash flow
- CapEx intensity
- Current ratio
- Debt/EBITDA
- Return on tangible assets
- Revenue growth 5Y 10.7%
- Earnings surprise, average 3.3%
- Earnings quality (operating cash flow / net income) 2.17
- Share dilution 1.1%
- Piotroski F-Score 5/9
Failed (9)
- ROIC 3.8%
- P/FCF 46.59
- P/B ratio 3.29
- Low reliance on intangibles
- Price below Graham Number
- DCF valuation (Overvalued)
- ROE 4.9%
- PEG ratio 25.86
- Net margin trend 6.0% vs 6.4%
Unavailable (2)
- Dividend payout –
- Interest coverage
Piotroski F-Score
Mixed signals: some areas need attention
Earnings Quality
High quality: earnings backed by cash
Share Dilution
Share count is stable
Institutional Holdings
Governance
Executive Team
| Name | Title | Age |
|---|---|---|
| Mr. Matthijs Glastra | CEO & Chairman of the Board | 56 |
| Mr. Robert J. Buckley | Chief Financial Officer | 51 |
| Mr. Alexander Manganiello | General Counsel & Corporate Secretary | 58 |
| Mr. Charles G. Ravetto | Co-Chief Operating Officer of Automation Enabling Technologies | 54 |
| Mr. John Lesica | Co-Chief Operating Officer of Medical Solutions | 49 |
| Mr. John Joseph Burke II | Chief Accounting Officer & Corporate Controller | 43 |
| Ms. Sarah Betadam | Chief Information Officer & Chief Information Security Officer | - |
| Ms. Nissia Sabri | Senior Vice President of Corporate Development | - |
| Mr. Liam Weston | Chief Human Resources Officer | - |
| Mr. Heinrich Dreyer | Group President of Medical Solutions | - |
Audit Risk
2
Board Risk
4
Compensation Risk
4
Shareholder Rights Risk
2
Documents
- View document
Annual Report (10-K)
A yearly overview of the business, its financial results, and the risks it faces.
Filed on 2026-02-23
- View document
Quarterly Report (10-Q)
A snapshot of financial performance for the most recent three-month period.
Filed on 2026-08-05
- View document
Current Report (8-K)
An announcement of a major event, such as a leadership change or big news.
Filed on 2026-08-05
via SEC EDGAR
Income History
via SEC EDGAR
Part 2 · The price and its context
This part shows how the price has behaved, not whether the company is worth owning. Inside: technical analysis, potential, historical drawdowns, gamma exposure.
Market Reaction Profile
How much NOVT moves, measured on its daily prices.
More volatile than 73% of the tracked stocks (90-day volatility).
- Volatility 30d
- 48.1%
- Volatility 90d
- 48.5%
- Beta vs S&P 500 (1y)
- 2.01Correlation 0.49
- Max drawdown (12m)
- -27.0%
- ATR (14d, % of price)
- 4.85%
Earnings reactions
How NOVT moved around its past quarterly results.
Next earnings release
Nov 9, 2026 · In 16 days · Time not known
EPS estimate: 0.97Revenue estimate: $301M
What usually happens
- Over the last 12 releases the stock moved a median of 6.0% the next day, up or down.
- Next-day moves: up 6, down 6 (out of 12).
- Of the 4 releases that beat estimates, the stock fell the next day after 2.
Release history
| Date | When | EPS est. | EPS actual | Surprise | Gap | 1 day | 5 days |
|---|---|---|---|---|---|---|---|
| Aug 5, 2026 | After the close | 0.85 | 0.89 | +5.1% | +10.7% | +6.7% | +9.1% |
| May 11, 2026 | After the close | 0.79 | 0.81 | +2.2% | +7.2% | +13.7% | +8.1% |
| Feb 23, 2026 | After the close | 0.90 | 0.91 | +1.4% | +4.4% | -3.5% | -1.2% |
| Nov 3, 2025 | After the close | 0.83 | 0.87 | +4.4% | -4.0% | -4.8% | -23.5% |
| Aug 5, 2025 | Before the open | n/a | n/a | n/a | -5.8% | -6.7% | -8.8% |
| May 6, 2025 | Before the open | n/a | n/a | n/a | -17.4% | -1.9% | +9.7% |
| Feb 25, 2025 | After the close | n/a | n/a | n/a | +0.2% | +0.7% | -5.7% |
| Nov 5, 2024 | Before the open | n/a | n/a | n/a | -8.3% | -5.5% | +2.6% |
| Aug 6, 2024 | Before the open | n/a | n/a | n/a | 0.0% | +8.7% | +9.5% |
| May 7, 2024 | Before the open | n/a | n/a | n/a | -1.9% | +0.4% | +1.0% |
| Feb 28, 2024 | Before the open | n/a | n/a | n/a | +0.7% | +6.4% | +7.9% |
| Nov 7, 2023 | Before the open | n/a | n/a | n/a | -6.1% | -13.5% | -10.4% |
Release dates from SEC 8-K filings.
Updated 10/24/2026
Historical statistics for educational purposes only. They are not forecasts and not investment advice.
Price reaction to the news
Latest news on NOVT and what the price did next.
- 3/4/2026PositiveNovanta Stock Has Underperformed This Past Year, but One Investor Just Made a $36 Million Bet on Shares
Published while the US market was open: the move of that day cannot be split into before and after the news, so no figure is shown.
- 2/22/2026NegativeIs Novanta Stock a Buy or Sell After Its CEO Dumped 6,500 Shares?
- +1 day
- -1.4%
- +3 days
- -9.3%
Return of the stock minus return of SPY over the same days. A news item close to a price move did not necessarily cause it. Historical data for educational purposes only, not investment advice.
Latest News
Recent headlines for NOVT.
- 3/4/2026POSITIVENovanta Stock Has Underperformed This Past Year, but One Investor Just Made a $36 Million Bet on Shares
Despite underperforming over the past year, Novanta Inc. (NOVT) has attracted a significant bet from an investor who purchased $36 million worth of shares. This bold move suggests strong conviction in the company's future recovery and growth potential. Novanta designs photonics and precision motion solutions for OEMs in medical and industrial markets globally. While the stock has lagged, this substantial investment could signal a turning point, indicating that the company's underlying value is underestimated by the market and may lead to a positive re-evaluation.
- 2/24/2026NEUTRALNovanta (NOVT) Q4 2025 Earnings Call Transcript
Markets Gazette notes the release of the earnings call transcript for Novanta Inc. (NOVT) concerning its fourth-quarter 2025 results. While specific financial figures and future projections have not yet been made public or analyzed herein, the availability of this document is a key event for investors. Earnings call transcripts provide direct insights into company performance, management strategies, challenges faced, and growth prospects, often revealing the tone and expectations of leadership. Shareholders and analysts will closely monitor this document for any implicit or explicit signals that could influence the stock's value in the short to medium term. The current lack of specific content necessitates a cautious approach, but the transcript remains a crucial resource for due diligence.
- 2/23/2026NEUTRALA Preview Of Novanta's Earnings
The Markets Gazette notes that investor focus is turning to Novanta Inc. ahead of its upcoming earnings release. The article, while providing no specific data, serves as a calendar marker for a key event that could define the stock's short-term trajectory. Analysts and the market are awaiting crucial figures such as revenue, earnings per share (EPS), and, most importantly, forward-looking guidance for the coming quarters. The stock's reaction will largely depend on how the actual results compare against consensus estimates. Until the official announcement, traders are likely to maintain a cautious stance, with trading volumes potentially increasing closer to the release date, signaling heightened anticipation.
- 2/22/2026NEGATIVEIs Novanta Stock a Buy or Sell After Its CEO Dumped 6,500 Shares?
Novanta Inc., a leader in photonics and precision motion solutions for OEMs, has experienced notable insider selling. The CEO recently offloaded 6,500 shares, a move that could signal diminished confidence in the company's future performance from top management. While Novanta operates in promising tech sectors, this insider action might concern investors, suggesting the current stock price could be considered high or that potential challenges lie ahead not yet fully reflected in the market. Investors should closely watch upcoming financial reports and operational performance to assess the impact of this sale.